ADVERTISEMENT
CTLA-4 Inhibitors for Patients With PD-L1–Negative/PD-L1<1% Lung Cancer
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, Rush University Medical Center, Chicago, Illinois, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1 <1% lung cancers.
“I believe we need more consistent data to inform the role of CTLA-4 inhibition in treatment of PD-L1 negative disease,” concluded Dr Paydary.
Transcript:
Hi my name is Koosha Paydary and I'm a medical oncologist and assistant professor of medicine at Rush University Medical Center. I'm here at the Great Debates and Updates in Lung Cancer 2024 in New York City. The topic of my talk is about the role of CTLA-4 inhibition in patients with lung cancer that have negative PD-L1 or PD-L1 of <1%.
Our clinical data from the updated results of the CheckMate 227 and the CheckMate 9LA are indicating that there might be a role for integration of CTLA-4 inhibition in treatment of this disease, which historically has been challenging and difficult to treat. However, when we look at across the board, looking at other trials that have looked at CTLA-4 inhibition in this disease, we do see some inconsistency. For example, in the POSEIDON trial, as well as the MYSTIC and the NEPTUNE trials.
In general, I believe we need more consistent data to inform the role of CTLA-4 inhibition in treatment of PD-L1–negative disease. We should also keep in mind that we need better biomarkers. There could be a role for molecular profiling. There is emerging data with respect to certain mutations, such as the STK11 and KEAP1, and we need more data to inform us on how those mutations can also play a role in integration of CTLA-4 inhibition.
Source:
Paydary, K. Debate: PD-L1 <1%: Is this the place for CTLA-4 inhibition in lung cancer? Presented at Great Debates & Updates in Lung Cancer; April 27-28, 2024; New York, NY.
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of OLN or HMP Global, their employees, and affiliates.
